Cambridge, UK-based Lucida Medical has earned a CE mark for Prostate Intelligence (Pi), its artificial intelligence-based software that can identify cancer in magnetic resonance imaging (MRI) scans of prostates.

The Pi software can help radiologists assess MRI images and accurately target biopsies where needed, the company said. Interpreting oncological MRIs is labor-intensive and requires specialist training, and the shortfall in the UK radiologist workforce is forecast to reach 43 percent by 2024.

“With around 20 million new cases of cancer diagnosed each year worldwide, there is enormous potential for us to improve patients’ outcomes and reduce costs for health systems” such as the UK’s National Health Service, said Antony Rix, Lucida’s CEO and co-founder.